Increasing focus on prophylactic treatment is a key driver for the global hemophilia drugs market
Extensive research carried out by the analysts at Technavio has shown that the global hemophilia drugs market will witness steady growth and will post a moderate CAGR of more than 5% over the forecast period. With an increasing focus on prophylactic treatment, the market for hemophilia drugs is expected to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline.
According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth.
Hemophilia drugs market based on geography
According to the hemophilia market overview, the Americas led the global hemophilia drugs market in 2015 and is expected to continue its dominance until the end of 2020. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on health care insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.
Hemophilia drugs market: Competitive landscape and key vendors
The global hemophilia drugs market highly consolidated with key players including Baxalta, Bayer, CSL Behring, Novo Nordisk, Biogen, and Pfizer, which together account for the majority of market shares. The vendors are focusing on opportunities in emerging markets such as China and India to increase their market share.
Some hemophilia drug companies are
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer
Hemophilia drugs market segmentation by type of disease
- Hemophilia A
- Inhibitors
- Hemophilia B
- Von Willebrand disease
During 2015, the Hemophilia A segment dominated the market and is expected to lead the market during the forecast period. Hemophilia A is more prevalent than hemophilia B and Von Willebrand disease. The development of novel drugs with prolonged action and the increased adoption of prophylactic treatment among individuals will boost this market segment’s growth in the future. The on-demand hemophilia A prophylactics are expected to witness greater acceptance in the emerging countries.
Hemophilia drugs market by type of therapy
- Recombinant therapies
- Plasma-derived therapies
According to the industry research analysts, the recombinant therapies segment accounted for most of the market revenue shares and will continue to lead the market over the coming years. The growth of this segment is attributed to the increasing demand for prophylaxis therapies in developed countries and shift in preference from plasma-derived therapies to recombinant products in the emerging economies. Moreover, the entry of long-acting recombinant products such as ALPROLIX by Biogen, Advate by Baxter, among others will contribute to this segment’s growth over the coming years.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global hemophilia drugs market?
- What are the key market trends impacting the growth of the global hemophilia drugs market?
- What are the challenges to market growth?
- Who are the key vendors in the global hemophilia drugs market?
- What are the market opportunities and threats faced by the vendors in the global hemophilia drugs market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global hemophilia drugs market?
Technavio also offers customization on reports based on specific client requirement.
Related reports
Table of Content
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 07: Market segmentation by type of disease
- Global hemophilia A drugs market
- Global hemophilia inhibitors treatment market
- Global hemophilia B drugs market
- Global von Willebrand disease treatment market
PART 08: Market segmentation by type of therapy
- Recombinant therapies
- Plasma-derived therapies
PART 09: Market segmentation by type of disease management
- Prophylaxis
- On-demand therapy
- Inhibitor therapy
PART 10: Geographical segmentation
- Hemophilia drugs market in Americas
- Hemophilia drugs market in EMEA
- Hemophilia drugs market in APAC
PART 11: Market drivers
- Focus on prophylactic treatment
- Drugs with prolonged action
- Improved diagnostic procedures
PART 12: Impact of drivers
PART 13: Market challenges
- Low diagnosis rate
- High entry barriers
- Cost-intensive complex treatment
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Increase in technological innovations
- Development of gene therapy products
- Centralized buyers should pave the way to increased penetration
PART 16: Vendor landscape
- Competitive scenario
- Other prominent vendors
PART 17: Key vendor analysis
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer
PART 18: Appendix
PART 19: Explore Technavio
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape